DC-CIK联合化疗对晚期结直肠癌患者免疫功能及B7-H4蛋白表达的影响

摘要

目的 探讨树突状细胞联合细胞因子诱导的杀伤细胞(DC-CIK)免疫治疗联合常规化疗对晚期结直肠癌患者免疫功能及B7-H4蛋白表达的影响.方法 选取2012年10月至2014年9月收治的晚期结直肠癌患者110例,随机分为两组,每组各55例.其中对照组接受常规化疗,观察组患者接受DC-CIK联合化疗.对比分析两组患者治疗后的免疫功能及B7-H4蛋白表达情况.结果 对照组患者接受治疗后其外周血中CD4+、CD8+和CD4+/CD8+无显著差异(P>0.05);而观察组患者接受治疗后外周血中CD4+和CD4+/CD8+显著升高,与对照组患者相比有显著差异(P0.05), while the peripheral blood CD4+ and CD4+/CD8+ ratio increased significantly in the observation group after treatment (P<0.05).The amount of tumor promoting molecules CD168, CD133 and CD151 was significantly decreased in the observation group compared with the control group , and the tumor inhibitory molecules of CD9, CD63 were significantly higher than those of the control group, whereas the level of IFN-γ significantly increased in the observation group, the difference was statistically significant (P<0.05).In addition, the soluble B7-H4 protein expression was significantly lower than that of the control group after treatment (P<0.05).Conclusion Compared with chemotherapy alone, DC-CIK combined with chemotherapy is helpful to improve the immune function of patients with advanced colorectal cancer, and it can reduce B7-H4 protein expression and inhibit tumor growth.Therefore, it is worthy of popularization and application in the treatment of advanced colorectal cancer.